Earnings call transcript: BlueScope posts strong H2 2026, stock slips 2.4%

BlueScope reported FY26 underlying EBIT of AUD 1.27B (second-half: AUD 716M) which came in above the top end of guidance, driven by stronger North America (North Star second-half EBIT +50%) and improved cost and productivity. The company increased shareholder returns to AUD 3.00/share for calendar 2026 via an AUD 0.65 final dividend plus an AUD 0.70 special dividend (8.08% dividend yield), while net debt ended at AUD 600M. Despite the earnings beat, the stock fell 2.4% to $32.88 as investors focused on FY27 as a transition year with elevated capex (~AUD 1.0B, first-half ~AUD 600M) and working-capital drag, with FY27H1 underlying EBIT guided to AUD 860M–AUD 960M.

Analysis

The market is still pricing this as a transition story, not a cash-yield story. That creates a window where near-term capex and working-capital drag obscure the more important mechanism: a structurally higher payout ratio with low leverage and a favorable lag in North American pricing resets. If U.S. benchmark spreads hold through the next contract cycle, the next two quarters can still surprise to the upside even without a big demand inflection.

The clearest winners are the branded/domestic steel franchises and any peers with pricing power; the losers remain export-exposed Asian mills and Australian commodity-linked producers that are trapped in weak spread conditions. A second-order effect is that BlueScope’s move toward a more explicit capital-return regime may pressure other industrials with strong balance sheets to prove they can either buy back stock or raise distributions, especially where growth capex is rolling off. The temporary noise from major project ramp-ups should compress reported growth but not underlying asset quality.

The contrarian view is that consensus is over-weighting the FY27 transition and under-weighting the normalization in cash conversion once the investment phase rolls off. What would break the thesis is not a small miss, but evidence that the BF6/MCL7 transition slips materially or that U.S. spreads mean-revert before the annual reset, which would remove the lag benefit and expose the stock’s still-cyclical multiple.

Key Decisions for Investors

• Buy BLSFY on a 3%-5% pullback or below AUD 33.0, 3-6 month horizon, targeting high-single-digit total return plus yield; thesis fails if FY27 H1 EBIT guidance drops below AUD 860m or BF6 cutover slips well beyond early H2.
• Enter a small relative-value long BLSFY / short STLD pair for investors wanting cash-return rerating over pure steel beta; exit if U.S. hot-rolled spreads roll over by >10% or STLD outperforms BLSFY by >8% over 4-6 weeks.
• Do not chase RIO here; treat it as a macro hedge only. This is a company-specific capital-allocation and spread-lag story, not a broad iron-ore upcycle.
• Set an alert for the next AGM/FY27 update: if management confirms BF6 timing and North American resets remain intact, add to BLSFY; if not, fade the post-earnings weakness.